RecruitingNCT03971487
Study of ocrelizumab for psychosis possibly linked to autoimmunity
About this title
Read the official source — NCT03971487Study assessmentsAges 18–35United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 35 years.
- Listed locations
- HoustonSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 1, 2019
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- The Methodist Hospital Research Institute
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Behavioural, Biological, Diagnostic test
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT03971487
- Official title
Show the full official title
Ocrelizumab for Psychoses Possibly Caused by Synaptic Autoimmunity
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is The Methodist Hospital Research Institute, a hospital or academic medical center.
Who can participate?
Listed age limits: 18 years to 35 years.
Is this study still recruiting?
The registry lists this study as recruiting.
